Caris Adds 14 New Markers to Breast Cancer PGx Test

"The recent biomarker additions expand the potential clinical utility to include women who face therapeutic ambiguity earlier in the disease continuum -- a group representing nearly 50 percent of all breast cancer patients," the company said.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.